J. Mihalic

发表

Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.

M. Lindstrom, J. Jaén, K. Dai, 2012, Bioorganic & medicinal chemistry letters.

Discovery of potent and specific CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a new class of ghrelin receptor antagonists.

M. Lindstrom, Liang Tang, M. Lizarzaburu, 2012, Bioorganic & medicinal chemistry letters.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.

Discovery of a novel series of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.

J. Jaén, K. Dai, P. Fan, 2011, Bioorganic & medicinal chemistry letters.

Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2.

M. Lindstrom, J. Jaén, Q. Ye, 2012, Bioorganic & medicinal chemistry letters.

Design and optimization of imidazole derivatives as potent CXCR3 antagonists.

B. Lemon, S. Miao, T. Sullivan, 2008, Bioorganic & medicinal chemistry letters.

Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction.

N. Walker, Zhulun Wang, Haoda Xu, 2012, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Homologous Phosphonic Acids and Sulfonic Acids as Inhibitors of Lumazine Synthase

A. Bacher, M. Cushman, J. Mihalic, 1999 .

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.

Y. Wang, J. Canon, M. Peterson, 2014, Journal of medicinal chemistry.

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

B. Lemon, T. Sullivan, G. Tonn, 2008, Bioorganic & medicinal chemistry letters.

Thermodynamic analysis of mRNA cap binding by the human initiation factor eIF4E via free energy perturbations.

N. Walker, S. Thibault, J. Mihalic, 2009, Journal of the American Chemical Society.

Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models

J. Jaén, K. Dai, Leping Li, 2013, Pharmacology research & perspectives.

Incorporation of an amide into 5-phosphonoalkyl-6-D-ribitylaminopyrimidinedione lumazine synthase inhibitors results in an unexpected reversal of selectivity for riboflavin synthase vs lumazine synthase.

R. Huber, A. Bacher, M. Fischer, 2002, The Journal of organic chemistry.

Design and synthesis of 6-(6-D-ribitylamino-2,4-dihydroxypyrimidin-5-yl)-1-hexyl phosphonic acid, a potent inhibitor of lumazine synthase.

A. Bacher, M. Cushman, J. Mihalic, 1999, Bioorganic & medicinal chemistry letters.

Design and Synthesis of 6‐(6‐D‐Ribitylamino‐2,4‐dihydroxypyrimidin‐5‐yl)‐1‐hexylphosphonic Acid, a Potent Inhibitor of Lumazine Synthase.

A. Bacher, M. Cushman, J. Mihalic, 1999 .

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Dahlia R. Weiss, A. Sands, C. Guiducci, 2020 .

Abstract 3423: NX-2127: A first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies

Brandon J. Bravo, Stephanie L. Yung, J. Mcintosh, 2023, Cancer Research.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

K. Pattabiraman, Zhulun Wang, C. Quéva, 2014, Journal of medicinal chemistry.